Oak Harvest Investment Services Has $1.56 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Oak Harvest Investment Services grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,219 shares of the medical device company’s stock after acquiring an additional 597 shares during the period. Oak Harvest Investment Services’ holdings in DexCom were worth $1,556,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. CX Institutional acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $286,000. Bank of New Hampshire acquired a new position in DexCom during the first quarter valued at approximately $1,508,000. abrdn plc raised its position in DexCom by 21.1% during the fourth quarter. abrdn plc now owns 380,535 shares of the medical device company’s stock valued at $47,221,000 after purchasing an additional 66,348 shares in the last quarter. Cerity Partners LLC grew its stake in shares of DexCom by 5,791.0% during the fourth quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company’s stock worth $57,574,000 after buying an additional 456,097 shares during the last quarter. Finally, Eagle Asset Management Inc. grew its stake in shares of DexCom by 21.5% in the fourth quarter. Eagle Asset Management Inc. now owns 1,756,216 shares of the medical device company’s stock worth $217,929,000 after purchasing an additional 310,728 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on DXCM shares. Redburn Atlantic started coverage on shares of DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price objective on the stock. UBS Group boosted their price objective on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Canaccord Genuity Group boosted their price objective on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Finally, Raymond James boosted their target price on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $140.33.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 659 shares of the company’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the sale, the executive vice president now owns 66,901 shares in the company, valued at approximately $7,646,115.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Kevin R. Sayer sold 49,633 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the completion of the transaction, the chief executive officer now directly owns 283,893 shares of the company’s stock, valued at approximately $39,262,401.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 659 shares of the stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the transaction, the executive vice president now directly owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The disclosure for this sale can be found here. Insiders have sold 55,735 shares of company stock worth $7,619,347 in the last quarter. Insiders own 0.30% of the company’s stock.

DexCom Stock Down 1.4 %

Shares of NASDAQ DXCM traded down $1.58 during trading on Thursday, hitting $110.91. 1,353,061 shares of the company traded hands, compared to its average volume of 2,967,693. The business’s fifty day moving average is $121.78 and its 200 day moving average is $125.47. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The firm has a market capitalization of $44.11 billion, a price-to-earnings ratio of 71.56, a P/E/G ratio of 2.75 and a beta of 1.16. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The firm had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. Equities research analysts predict that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.